Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold at BidaskClub

Share on StockTwits

Esperion Therapeutics (NASDAQ:ESPR) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, June 1st, BidAskClub reports.

A number of other research analysts have also recently weighed in on the stock. Citigroup set a $73.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 28th. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Stifel Nicolaus restated a “buy” rating and issued a $112.00 price objective on shares of Esperion Therapeutics in a report on Friday, March 29th. Credit Suisse Group boosted their price target on shares of Esperion Therapeutics from $79.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, May 6th. Finally, Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 8th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $75.27.

Shares of ESPR stock opened at $49.59 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -6.58 and a beta of 1.87. Esperion Therapeutics has a 12 month low of $36.06 and a 12 month high of $60.99.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $3.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $2.43. The company had revenue of $145.42 million during the quarter, compared to analysts’ expectations of $69.35 million. During the same period last year, the firm posted ($1.73) earnings per share. As a group, equities analysts predict that Esperion Therapeutics will post -2.1 EPS for the current fiscal year.

In related news, CEO Timothy M. Mayleben bought 5,000 shares of the stock in a transaction dated Friday, March 29th. The stock was acquired at an average price of $40.00 per share, for a total transaction of $200,000.00. Following the acquisition, the chief executive officer now owns 61,163 shares in the company, valued at approximately $2,446,520. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Richard Bartram sold 8,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $42.88, for a total transaction of $343,040.00. The disclosure for this sale can be found here. In the last quarter, insiders have acquired 65,000 shares of company stock valued at $3,155,550 and have sold 48,329 shares valued at $2,280,206. Insiders own 7.70% of the company’s stock.

Several institutional investors have recently modified their holdings of ESPR. Advisor Group Inc. boosted its holdings in shares of Esperion Therapeutics by 44.4% in the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 291 shares in the last quarter. Parallel Advisors LLC purchased a new stake in Esperion Therapeutics in the 1st quarter valued at $80,000. Rehmann Capital Advisory Group purchased a new stake in Esperion Therapeutics in the 4th quarter valued at $97,000. Marshall Wace North America L.P. purchased a new stake in Esperion Therapeutics in the 1st quarter valued at $164,000. Finally, Marshall Wace LLP purchased a new stake in Esperion Therapeutics in the 1st quarter valued at $186,000.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: Current Ratio

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.